Stockscreener 앱 받기
1.23
16.59%
0.175
시간 외 거래:
1.15
-0.08
-6.50%
AIM ImmunoTech Inc 주식(AIM)의 최신 뉴스
AIM ImmunoTech Inc. (AIM) stock: surges as pancreatic cancer trial shows survival breakthrough - parameter.io
AIM ImmunoTech reports year-end positive phase 2 interim progress for Ampligen® (rintatolimod) plus AstraZeneca's Imfinzi® (durvalumab) in pancreatic cancer - marketscreener.com
AIM ImmunoTech reports data in year-end update from Phase 2 trial of Ampligen - TipRanks
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
AIM ImmunoTech (AIM) Announces Positive Phase 2 Trial Results for Ampligen - GuruFocus
AIM ImmunoTech’s $12M Rights Offering: Implications and Prospects - StocksToTrade
Why Is AIM ImmunoTech Stock Up Today? - TipRanks
AIM ImmunoTech Rights Offering Targets $12 Million Boost - timothysykes.com
AIM ImmunoTech Provides Interim DURIPANC Clinical Progress Update - TipRanks
AIM ImmunoTech Inc Provides Interim Update on DURIPANC Study - TradingView
AIM ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer - Chartmill
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Are Medical Stocks Lagging AIM ImmunoTech (AIM) This Year? - Yahoo Finance
AIM ImmunoTech Announces Changes to Key Dates and Terms Related to Announced Rights Offering - The Manila Times
AIM ImmunoTech Announces Key Dates and Terms Related to Announced Rights Offering - GlobeNewswire
AIM ImmunoTech Stock Trading Halted, Pending Material News Release - marketscreener.com
Cancer drug developer plans $12M raise to fund pancreatic trial costs - Stock Titan
AIM ImmunoTech Adjusts Class E Warrant Terms After Dividend - TipRanks
AIM ImmunoTech Inc Modifies Class E and F Warrants - TradingView
Why AIM ImmunoTech Inc. (HXB) stock gets analyst attentionSupport Zone Identification & The Smart Money Is Buying These Picks - bollywoodhelpline.com
AIM ImmunoTech granted U.S. patent for Ampligen - MSN
AIM ImmunoTech Highlights Ampligen Development Risks and Plans - The Globe and Mail
Trend Recap: How AIM ImmunoTech Inc stock compares with tech leadersDollar Strength & Entry Point Confirmation Signals - Bộ Nội Vụ
AIM ImmunoTech (NYSEAMERICAN:AIM) Upgraded at Zacks Research - Defense World
AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week - MSN
Rate Cut: Is AIM ImmunoTech Inc HXB stock undervalued after correctionMarket Activity Summary & Free Expert Verified Stock Movement Alerts - Bộ Nội Vụ
AIM ImmunoTech Inc.: - MarketScreener
Is AIM ImmunoTech (AIM) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
AIM ImmunoTech (NYSEAMERICAN:AIM) Shares to Split on Friday, January 9th - Defense World
AIM ImmunoTech: One Shr for Every 1,000 Shrs or for Every Outstanding Option or Warrant Having a Right to Stk Dividends >AIM - 富途牛牛
AIM ImmunoTech Announces Stock Dividend - The Manila Times
AIM ImmunoTech to give extra shares to investors via stock dividend - Stock Titan
AIM ImmunoTech receives NYSE American notice of delisting and appeal - MSN
Published on: 2025-12-21 18:10:19 - Улправда
Why AIM ImmunoTech Inc. (HXB) stock is a must watch tickerPortfolio Value Report & Stepwise Entry/Exit Trade Alerts - Улправда
How AIM ImmunoTech Inc. (HXB) stock performs during market turbulenceJuly 2025 Recap & Trade Opportunity Analysis Reports - DonanımHaber
Will AIM ImmunoTech Inc. stock benefit from sector leadershipRate Cut & Real-Time Price Movement Reports - DonanımHaber
Published on: 2025-12-19 13:37:56 - Улправда
AIM ImmunoTech Completes 2025 Annual Stockholder Meeting - TipRanks
[8-K] AIM ImmunoTech Inc. Reports Material Event | AIM SEC FilingForm 8-K - Stock Titan
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B - Benzinga
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B - Sahm
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B (2025-12-16) - Seeking Alpha
AIM ImmunoTech Announces Release of the Next CEO Corner Segment - Yahoo Finance
Ascendiant Capital Maintains AIM ImmunoTech (AIM) Buy Recommendation - Nasdaq
Ascendiant Capital lowers AIM ImmunoTech stock price target to $22 on valuation - Investing.com Nigeria
Ascendiant Capital lowers AIM ImmunoTech stock price target to $22 on valuation By Investing.com - Investing.com South Africa
AIM: Analyst Maintains 'Buy' Rating, Lowers Price Target | AIM S - GuruFocus
Would You Still Hold AIM ImmunoTech Stock If It Fell Another 30%? - Trefis
How AIM ImmunoTech Inc. stock compares with tech leadersEarnings Recap Summary & Growth-Oriented Investment Plans - Newser
Will AIM ImmunoTech Inc. stock benefit from Fed rate cutsMarket Trend Report & Free Technical Confirmation Trade Alerts - Newser
How AIM ImmunoTech Inc. stock reacts to new regulations2025 Top Gainers & Reliable Volume Spike Alerts - Newser
Will AIM ImmunoTech Inc. stock deliver compounding returnsJuly 2025 Earnings & Daily Risk Controlled Trade Plans - Newser
Can AIM ImmunoTech Inc. stock expand revenue streamsDollar Strength & Fast Moving Stock Trade Plans - Newser
0.96%
2.92%
자본화:
|
볼륨(24시간):